Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumatinib Maintenance After Allogeneic HSCT in Ph+ ALL
ChiCTR2500106532Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of Flumatinib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Overall survival at 2 years after allo-SCT. Started Jul 2025; status: recruiting.
02
Drugs
Flumatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2500106532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106532.